How and where to order Noroxin (Norfloxacin) 100, 200, 400 mg tablets or capsules online:
|Prices:||from $0.32 per pill
|Discount:||10% coupon: DFHDCC
|Forms:||100 mg, 200 mg, 400 mg tablets
|Type:||Norfloxacin brand, Noroxin generic
|Payment:||Visa, MasterCard, AmEx, Bitcoin
|Delivery:||Regular and express mail service
|Shipping:||Worldwide, including USA, UK, Europe, Canada, Australia
Norfloxacin (trade names include Noroxin, Baccidal, Floxatral, Floximed, Fortimax, Fulgram, Gyrablock, Lexinor, Nolicin, Norbactin, Norflohexal, Norfloxacin Sandoz, Norfloxacine Arrow Generiques, Noroxine, Norxacin, Nufloxib, Oranor, Quinoform, Respexil, Trizolin, Uritrat, Urobacid, Uroctal, Uroseptal, Zoroxin) is an antibacterial medication from fluoroquinolones pharmacological group. This medicine is used to treat various bacterial infections, including eye, ear, prostate, bladder, urinary tract, kidney, gynecological infections, epididymitis, cystitis, gastroenteritis, traveler's diarrhea, shigellosis, prostatitis, conjunctivitis, otitis, typhoid fever, paratyphoid fever, some sexually transmitted diseases such as syphilis, urethral and cervical gonorrhea, for prevention of spontaneous bacterial peritonitis, in veterinary medicine. Norfloxacin works by killing sensitive bacteria.
Amoxicillin, Clavulanic Acid (Augmentin)
Sulfamethoxazole, Trimethoprim (Bactrim)
Pharmacological and medical categories:
Ear care medicines
Eye care products
Veterinary, pet meds
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01M - Quinolone antibacterials
J01MA - Fluoroquinolones
J01MA06 - Norfloxacin
S - Sensory organs
S01 - Ophthalmologicals
S01A - Antiinfectives
S01AE - Fluoroquinolones
S01AE02 - Norfloxacin
Typhoid and paratyphoid fevers - A01
Shigellosis - A03
Diarrhoea and gastroenteritis of presumed infectious origin - A09
Infections with a predominantly sexual mode of transmission - A50-A64
Gonococcal infection - A54
Conjunctivitis - H10
Suppurative and unspecified otitis media - H66
Peritonitis - K65
Spontaneous bacterial peritonitis - K65.2
Acute tubulo-interstitial nephritis - N10
Chronic tubulo-interstitial nephritis - N11
Cystitis - N30
Urethritis and urethral syndrome - N34
Inflammatory diseases of prostate - N41
Orchitis and epididymitis - N45
Salpingitis and oophoritis - N70
Inflammatory disease of uterus, except cervix - N71
Inflammatory disease of cervix uteri - N72
Need for other prophylactic measures - Z29
Indications and usage:
Noroxin (Norfloxacin) is indicated for the treatment of adults with the following infections caused by susceptible strains of the designated microorganisms:
Urinary tract infections
Uncomplicated urinary tract infections (including cystitis) due to Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, Staphylococcus saprophyticus, Citrobacter freundii, Enterobacter aerogenes, Enterobacter cloacae, Proteus vulgaris, Staphylococcus aureus, or Streptococcus agalactiae.
Complicated urinary tract infections due to Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, or Serratia marcescens.
Sexually transmitted diseases
Uncomplicated urethral and cervical gonorrhea due to Neisseria gonorrhoeae.
Prostatitis due to Escherichia coli.
Penicillinase production should have no effect on norfloxacin activity.
Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to norfloxacin. Therapy with norfloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be given. Repeat culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agents but also on the possible emergence of bacterial resistance.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Noroxin and other antibacterial drugs, Norfloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. W hen culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Noroxin (Norfloxacin) is contraindicated in persons with a history of hypersensitivity, tendinitis, or tendon rupture associated with the use of norfloxacin or any member of the quinolone group of antimicrobial agents.
Dosage and administration:
Norfloxacin (Noroxin) tablets should be taken at least one hour before or at least two hours after a meal or ingestion of milk and/or other dairy products. Multivitamins, other products containing iron or zinc, antacids containing magnesium and aluminum, sucralfate, or Videx (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution, should not be taken within 2 hours of administration of norfloxacin. Noroxin pills should be taken with a glass of water. Patients receiving this medication should be well hydrated.
No significant lethality was observed in male and female mice and rats at single oral doses of norfloxacin up to 4 g/kg.
In the event of acute overdosage, the stomach should be emptied by inducing vomiting or by gastric lavage, and the patient carefully observed and given symptomatic and supportive treatment. Adequate hydration must be maintained.
Tendinopathy and tendon rupture
Exacerbation of myasthenia gravis
Central nervous system effects/disorders
Clostridium difficile associated diarrhea
Needle-shaped crystals were found in the urine of some volunteers who received either placebo, 800 mg norfloxacin, or 1600 mg norfloxacin (at or twice the recommended daily dose, respectively) while participating in a double-blind, crossover study comparing single doses of norfloxacin with placebo. W hile crystalluria is not expected to occur under usual conditions with a dosage regimen of 400 mg b.i.d., as a precaution, the daily recommended dosage should not be exceeded and the patient should drink sufficient fluids to ensure a proper state of hydration and adequate urinary output.
Alteration in dosage regimen is necessary for patients with impaired renal function.
Moderate to severe photosensitivity/phototoxicity reactions, the latter of which may manifest as exaggerated sunburn reactions (e.g., burning, erythema, exudation, vesicles, blistering, edema) involving areas exposed to light (typically the face, "V" area of the neck, extensor surfaces of the forearms, dorsa of the hands), can be associated with the use of quinolone antibiotics after sun or UV light exposure. Therefore, excessive exposure to these sources of light should be avoided. Drug therapy should be discontinued if phototoxicity occurs. Rarely, hemolytic reactions have been reported in patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity who take quinolone antibacterial agents, including norfloxacin. Prescribing Noroxin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Adverse reactions, side effects:
The most common adverse experiences ( > 1.0%) were:
Additional reactions (0.3%-1.0%) were:
tingling of the fingers
Use in specific populations:
Teratogenic Effects: Norfloxacin has been shown to produce embryonic loss in monkeys when given in doses 10 times2 the maximum daily total human dose (on a mg/kg basis). At this dose, peak plasma levels obtained in monkeys were approximately 2 times those obtained in humans. There has been no evidence of a teratogenic effect in any of the animal species tested (rat, rabbit, mouse, monkey) at 6-50 times the maximum daily human dose (on a mg/kg basis). There are, however, no adequate and well-controlled studies in pregnant women. Norfloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether norfloxacin is excreted in human milk.
When a 200 mg dose of Noroxin was administered to nursing mothers, norfloxacin was not detected in human milk. However, because the dose studied was low, because other drugs in this class are secreted in human milk, and because of the potential for serious adverse reactions from norfloxacin in nursing infants, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
The safety and effectiveness of oral norfloxacin in pediatric patients and adolescents below the age of 18 years have not been established. Norfloxacin causes arthropathy in juvenile animals of several animal species.
Geriatric patients are at increased risk for developing severe tendon disorders including tendon rupture when being treated with a fluoroquinolone such as Noroxin. This risk is further increased in patients receiving concomitant corticosteroid therapy. Tendinitis or tendon rupture can involve the Achilles, hand, shoulder, or other tendon sites and can occur during or after completion of therapy; cases occurring up to several months after fluoroquinolone treatment have been reported. Caution should be used when prescribing Noroxin (Norfloxacin) to elderly patients, especially those on corticosteroids. Patients should be informed of this potential side effect and advised to discontinue Noroxin and contact their healthcare provider if any symptoms of tendinitis or tendon rupture occur.
C - Australia
C - United States (Risk cannot be ruled out)
Salts and other forms:
Synonyms, international and chemical names:
Brands, generics, trade names:
Androfloxin - Teuto-Brasileiro Laboratorio
Apo-Norflox - Apotex
Baccidal - Abbott
Bacigyl - Aristo Pharmaceuticals
Bexinor - Beacons Pharmaceuticals
Bio-Tarbun - Duncan Laboratorios
Chibroxin - Merck
Chibroxine - Merck, Thea Laboratoires
Flox - Hexal
Floxacin - Merck, Productos Medix, Stada
Floxatral - Austral Laboratorios
Floximed - Burapha Dispensary
Fortimax - Merck
Fulgram - Labomed Instituto Farmaceutico
Gyrablock - Medochemie, Derek Marketing
Janacin - Biolab, Biopharm Chemicals, Medispec, Mekim
Lexfor - TNP Health Care
Lexinor - AstraZeneca
Medic Nor - Medicpharma
Memento-NF - Merck
M-Flox - Millimed
Microxin - Rayere Farmaceuticos
Nolicin - KRKA
Noracin - Chew Brothers, CIBRAN Companhia Brasileira de Antibioticos
Norbactin - Ranbaxy
Norflohexal - Hexal
Norflosal - TAD Pharma
Norflox - Azupharma, Cipla, CT-Arzneimittel, Sandoz
Norfloxacin - Aliud Pharma, Helvepharm, Novopharm, Ranbaxy, Ratiopharm, Sandoz, Stada, Teva
Norfloxacine - Biogaran, EG Labo, Merck, Mylan, Pro Doc, Ratiopharm, Sandoz, Sanofi-Aventis, Teva
Norfloxacino - Sandoz
Noroxin - Merck
Norquinol - Euromex Laboratorios
Norxacin - Globo Laboratorio, Siam Pharmaceutical
Novo-Norfloxacin - Novopharm
Nufloxib - Alphapharm
Oranor - A.F. Laboratorios, Aplicaciones Farmaceuticas
Quinoform - EMS Industria Farmaceutica
Respexil - Merck
Roxin - Arrow Pharmaceuticals
Trizolin - Remedica, Goldplus Universal, IDS Group, JDH Pharmaceutical, Pharmadica
Uritracin - Great Eastern Drug, BioFemme, Olic Thailand, United Laboratories
Uritrat - Libbs Farmaceutica
Urobacid - Novartis
Uroctal - Almirall, Sincerity Asia
Uroflox - Bial Laboratorios, Farmion Laboratorio Brasileiro de Farmacologia, Torrent Pharmaceuticals
Urofos - Panalab Laboratorios
Uroseptal - Merck, Bago Laboratorios
Urotem - Temis Lostalo Laboratorios
Uroxacin - Dr. Lazar Laboratorio
Utin - Cipla
Utinor - Merck, JustRight Pharmaceuticals, Neopharmed, Unison Laboratories
Zoroxin - Merck
APIs used in medicine in combinations with norfloxacin:
Lactic Acid Bacillus
Here is a list of popular medications containing norfloxacin as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
|Trade name of the drug
||Pharmaceutical forms and doses
||Capsules; Oral; Norfloxacin 200 mgPowder for Suspension; Oral; Norfloxacin 100 mg / 5 mlTablets; Oral; Norfloxacin 50 mgTablets; Oral; Norfloxacin 100 mgTablets; Oral; Norfloxacin 200 mgTablets; Oral; Norfloxacin 400 mg
||AbbottChong Kun Dang PharmaceuticalGray's PharmaceuticalsKyorin PharmaceuticalShinlin Sinseng Pharmaceutical
||Solution; Ophthalmic; Norfloxacin 0.3%Tablets, Film-Coated; Oral; Norfloxacin 400 mg
||MerckDynamic LaboratoriesFarmila-Thea FarmaceuticiOBS HealthcareShire
||Suspension; Oral; Norfloxacin 100 mg / 5 mlSyrup; Oral; Norfloxacin 100 mg / 5 mlTablets, Film-Coated; Oral; Norfloxacin 400 mg
||NovartisBiochemieF.P. MarketingIDS GroupMedical SuppliesSandozSigma LaboratoriesSvizera HealthcareTyrol Pharma
Norfloxacin main article on Wikipedia: https://en.wikipedia.org/wiki/Norfloxacin
Norfloxacin compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Norfloxacin
Norfloxacin Hydrochloride compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Norfloxacin-hydrochloride
Norfloxacin on DrugBank: https://go.drugbank.com/drugs/DB01059
Norfloxacin containing drugs on Drugs-About.com: https://drugs-about.com/ing/norfloxacin.html
Norfloxacin for sale on Pharma Doctor: https://pharma-doctor.com/norfloxacin.html
Norfloxacin international drug names on Drugs.com: https://www.drugs.com/international/norfloxacin.html
Noroxin (Norfloxacin) 400 mg tablets official prescribing information and medication guide from the U.S. FDA (revised 07/2013): https://www.accessdata.fda.gov/drugsatfda_docs/label...
Noroxin (Norfloxacin) 400 mg tablets medication guide from the U.S. FDA (revised 07/2016): https://www.fda.gov/media/79897/download
Noroxin (Norfloxacin, MSD) tablets product information from GP2U TeleHealth (revised 6 June 2012): https://gp2u.com.au/static/pdf/N/NOROXIN-PI.pdf
Arrow-Norfloxacin 400 mg tablets consumer medicine information from Medsafe (revised 28 April 2017): https://www.medsafe.govt.nz/consumers/cmi/a/arrow-norfloxacin.pdf
Revised: March 2021
Home | First Aid | Imprint | Short CV | Memberships | Publications | Lectures | Site Map | Contact
Copyright © 2012 - 2021 Daniel Kruschinski, MD. All Rights Reserved.